https://orcid.org/0000-0001-6519-1926
References
- Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatol Oxf Engl. 2010;49:1726–1733.
- Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433–440.
- Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719–1726.
- Horai Y, Isomoto E, Koga T, et al. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol. 2013;23:190–194.
- Nakashima R, Mimori T. [Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia]. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36:71–76.
- Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11:906–917.
- Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: current and future perspectives. Expert Rev Neurother. 2011;11:1265–1276.
- Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585–596.
- Tazelaar HD, Viggiano RW, Pickersgill J, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990;141:727–733.
- Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013;107:745–752.
- Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency. Ther Adv Neurol Disord. 2010;3:161–171.
- Kumai Y, Seguchi O, Sato T, et al. Reversible cerebral vasoconstriction syndrome after heart transplantation: a case report. Transplant Proc. 2017;49:2415–2418.
- Takemaru M, Takeshima S, Hara N, et al. [Reversible cerebral vasoconstriction syndrome: a clinical study of 11 cases]. Rinsho Shinkeigaku. 2018;58:377–384.
- Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:1496–1501.
- Koyama RVL, Braga TKK, da Silva Dias GA, et al. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. Clin Rheumatol. 2017;36:1919–1926.
- Tsuchiya H, Tsuno H, Inoue M, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014;24:694–696.
- Shima K, Sakagami T, Ichikawa K, et al. Successful treatment in a case of interstitial lung disease with clinically amyopathic dermatomyositis with positive anti-CADM-140/MDA5 antibodies by the administration of prednisolone, cyclosporin A, and mycophenolate mofetil. Ann Jpn Respir Soc. 2015;4:76–79.
- Hoa S, Troyanov Y, Fritzler MJ, et al. Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. Scand J Rheumatol. 2018;47:210–224.
- Huang K, Vinik O, Shojania K, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int. 2019;39:1971–1981.